Tonix Pharmaceuticals Holding Corp., a company specializing in the development of therapies for central nervous system (CNS) disorders, recently announced significant developments regarding its intellectual property rights. The company, which focuses on treatments for conditions such as fibromyalgia syndrome (FM) and post-traumatic stress disorder (PTSD), is listed on the Nasdaq stock exchange and operates within the biotechnology sector of the health care industry.
On October 1, 2026, Tonix Pharmaceuticals filed a current report disclosing that it received a Paragraph IV patent-certification notice from Dr. Reddy’s Laboratories. This notice pertains to Tonix’s cyclobenzaprine sublingual product, TONMYA®. The notice from Dr. Reddy’s Laboratories suggests that the generic applicant believes the U.S. patents listed in the FDA Orange Book for TONMYA® may be invalid or unenforceable.
In response to this notice, Tonix Pharmaceuticals has expressed its intention to vigorously enforce its intellectual property rights. The company has acknowledged that the outcome of any potential litigation remains uncertain. The filing also included forward-looking statements regarding the potential timing and impact of generic competition, the status of the patents, and the possible delay of FDA approval for the generic application. However, no specific financial figures were provided in the report.
As of October 1, 2026, Tonix Pharmaceuticals’ stock closed at $8.91, with a 52-week high of $24.49 recorded on October 6, 2025, and a 52-week low of $8.69 on October 1, 2026. The company’s market capitalization stands at approximately $152.82 million. The price-to-earnings ratio is currently -0.71, reflecting the company’s financial performance and market valuation.
Tonix Pharmaceuticals continues to focus on its mission to develop innovative therapies for CNS disorders, and stakeholders are closely monitoring the developments related to its patent enforcement efforts and the potential impact on its market position. For more detailed information about Tonix Pharmaceuticals’ work and offerings, interested parties can visit their website at www.tonixpharma.com .
